
What is claimed is:

1. A pharmaceutical composition comprising Compound 1:



1,

or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, and a carrier or diluent.

2. The pharmaceutical composition of claim 1, wherein the carrier or diluent is mannitol.

3. The pharmaceutical composition of claim 2, further comprising a glidant, an acidifier, a lubricant, or a mixture thereof.

4. The pharmaceutical composition of claim 2, comprising: 1) Compound 1, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, at an amount of from about 0.05 to about 3 % w/w; 2) mannitol at an amount of from about 80 to about 98 % w/w; 3) a glidant at an amount of from about 0 to about 10 % w/w; 4) an acidifier at an amount of from about 0 to about 6 % w/w; and 5) a lubricant at an amount of from about 0 to about 8 % w/w.

5. The pharmaceutical composition of claim 4, wherein Compound 1, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, is free base of Compound 1.

6. The pharmaceutical composition of claim 5, wherein the free base of Compound 1 is a crystalline free base of Compound 1.

7. The pharmaceutical composition of claim 5, wherein the free base of Compound 1 is characterized by an XRPD pattern comprising peaks at approximately 14.6, 18.2, and 18.3º 2θ.

8. The pharmaceutical composition of any one of claims 4 to 7, wherein the amount of Compound 1, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, is from about 0.1 to about 1.5 % w/w.

9. The pharmaceutical composition of claim 8, wherein the amount of Compound 1, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, is from about 0.13 to about 1 % w/w.

10. The pharmaceutical composition of any one of claims 4 to 9, wherein the amount of mannitol is from about 85 to about 95 % w/w.

11. The pharmaceutical composition of claim 10, wherein the amount of mannitol is from about 90 to about 93 % w/w.

12. The pharmaceutical composition of any one of claims 4 to 11, wherein the glidant is silica dimethyl silylate or colloidal silicon dioxide.

13. The pharmaceutical composition of any one of claims 4 to 12, wherein the amount of the glidant is from about 0.25 to about 3 % w/w.

14. The pharmaceutical composition of claim 13, wherein the amount of the glidant is from about 0.5 to about 2 % w/w.

15. The pharmaceutical composition of any one of claims 4 to 14, wherein the acidifier is fumaric acid.

16. The pharmaceutical composition of any one of claims 4 to 15, wherein the amount of the acidifier is from about 2 to about 5 % w/w.

17. The pharmaceutical composition of claim 16, wherein the amount of the acidifier is about 3 % w/w.

18. The pharmaceutical composition of any one of claims 4 to 17, wherein the lubricant is stearic acid.

19. The pharmaceutical composition of any one of claims 4 to 18, wherein the amount of the lubricant is from about 2 to about 6 % w/w.

20. The pharmaceutical composition of claim 19, wherein the amount of the lubricant is about 4 % w/w.

21. The pharmaceutical composition of claim 4, comprising: 1) Compound 1 at an amount of about 0.13 % w/w; 2) mannitol at an amount of about 92.37 % w/w; 3) silica dimethyl silylate at

an amount of about 0.5 % w/w; 4) fumaric acid at an amount of about 3 % w/w; and 5) stearic acid at an amount of about 4 % w/w.

22. The pharmaceutical composition of claim 21, having a total weight of about 75 mg.

23. The pharmaceutical composition of claim 22, which is contained in a size 4 capsule.

24. The pharmaceutical composition of claim 4, comprising: 1) Compound 1 at an amount of about 0.5 % w/w; 2) mannitol at an amount of about 91.5 % w/w; 3) colloidal silicon dioxide at an amount of about 1 % w/w; 4) fumaric acid at an amount of about 3 % w/w; and 5) stearic acid at an amount of about 4 % w/w.

25. The pharmaceutical composition of claim 24, having a total weight of about 100 mg.

26. The pharmaceutical composition of claim 25, which is contained in a size 3 capsule.

27. The pharmaceutical composition of claim 4, comprising: 1) Compound 1 at an amount of about 1 % w/w; 2) mannitol at an amount of about 90 % w/w; 3) colloidal silicon dioxide at an amount of about 2 % w/w; 4) fumaric acid at an amount of about 3 % w/w; and 5) stearic acid at an amount of about 4 % w/w.

28. The pharmaceutical composition of claim 27, having a total weight of about 200 mg.

29. The pharmaceutical composition of claim 28, which is contained in a size 2 capsule.

30. The pharmaceutical composition of claim 1, wherein the carrier or diluent is a mixture of starch and lactose.

31. The pharmaceutical composition of claim 30, further comprising a glidant, an acidifier, a lubricant, a disintegrant, or a mixture thereof.

32. The pharmaceutical composition of claim 30, comprising: 1) Compound 1, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, at an amount of from about 0.05 to about 3 % w/w; 2) a mixture of starch and lactose at an amount of from about 70 to about 90 % w/w; 3) a glidant at an amount of from about 0 to about 10 % w/w; 4) an acidifier at an amount of from about 0 to about 8 % w/w; 5) a lubricant at an amount of from about 0 to about 8 % w/w; and 6) a disintegrant at an amount of from about 0 to about 20 % w/w.

33. The pharmaceutical composition of claim 32, wherein Compound 1, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, is free base of Compound 1.

34. The pharmaceutical composition of claim 33, wherein the free base of Compound 1 is a crystalline free base of Compound 1.

35. The pharmaceutical composition of claim 33, wherein the free base of Compound 1 is characterized by an XRPD pattern comprising peaks at approximately 14.6, 18.2, and 18.3º 2θ.

36. The pharmaceutical composition of any one of claims 32 to 35, wherein the amount of Compound 1, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, is from about 0.1 to about 1.5 % w/w.

37. The pharmaceutical composition of claim 36, wherein the amount of Compound 1, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, is from about 0.13 to about 1 % w/w.

38. The pharmaceutical composition of any one of claims 32 to 37, wherein the starch is partially pregelatinized starch.

39. The pharmaceutical composition of any one of claims 32 to 38, wherein the lactose is anhydrous lactose.

40. The pharmaceutical composition of any one of claims 32 to 39, wherein the amount of the starch is from about 17 to about 22 % w/w, and the amount of the lactose is from about 53 to about 68 % w/w.

41. The pharmaceutical composition of any one of claims 32 to 39, wherein the amount of the mixture of starch and lactose is from about 75 to about 85 % w/w.

42. The pharmaceutical composition of claim 41, wherein the amount of the starch is from about 18 to about 21 % w/w, and the amount of the lactose is from about 57 to about 64 % w/w.

43. The pharmaceutical composition of any one of claims 32 to 39, wherein the amount of the mixture of starch and lactose is from about 80 to about 82 % w/w.

44. The pharmaceutical composition of claim 43, wherein the amount of the starch is from about 19 to about 20 % w/w, and the amount of the lactose is from about 61 to about 62 % w/w.

45. The pharmaceutical composition of any one of claims 32 to 39, wherein the weight ratio of the starch to the lactose is from about 1:2 to about 1:4.

46. The pharmaceutical composition of claim 45, wherein the weight ratio of the starch to the lactose is from about 1:3 to about 1:3.3.

47. The pharmaceutical composition of any one of claims 32 to 46, wherein the glidant is silica dimethyl silylate or colloidal silicon dioxide.

48. The pharmaceutical composition of any one of claims 32 to 47, wherein the amount of the glidant is from about 0.25 to about 3 % w/w.

49. The pharmaceutical composition of claim 48, wherein the amount of the glidant is from about 0.5 to about 1 % w/w.

50. The pharmaceutical composition of any one of claims 32 to 49, wherein the acidifier is fumaric acid.

51. The pharmaceutical composition of any one of claims 32 to 50, wherein the amount of the acidifier is from about 2 to about 6 % w/w.

52. The pharmaceutical composition of claim 51, wherein the amount of the acidifier is about 4 % w/w.

53. The pharmaceutical composition of any one of claims 32 to 52, wherein the lubricant is stearic acid.

54. The pharmaceutical composition of any one of claims 32 to 53, wherein the amount of the lubricant is from about 2 to about 6 % w/w.

55. The pharmaceutical composition of claim 54, wherein the amount of the lubricant is about 4 % w/w.

56. The pharmaceutical composition of any one of claims 32 to 55, wherein the disintegrant is sodium starch glycolate.

57. The pharmaceutical composition of claim 56, wherein the amount of the disintegrant is from about 5 to about 15 % w/w.

58. The pharmaceutical composition of claim 57, wherein the amount of the disintegrant is about 10 % w/w.

59. The pharmaceutical composition of claim 32, comprising: 1) Compound 1 at an amount of about 0.13 % w/w; 2) partially pregelatinized starch at an amount of about 20 % w/w and anhydrous lactose at an amount of about 61.4 % w/w; 3) silica dimethyl silylate at an amount of about 0.5 % w/w; 4) fumaric acid at an amount of about 4 % w/w; 5) stearic acid at an amount of about 4 % w/w; and 6) sodium starch glycolate at an amount of about 10 % w/w.

60. The pharmaceutical composition of claim 59, having a total weight of about 75 mg.

61. The pharmaceutical composition of claim 60, which is contained in a size 4 capsule.

62. The pharmaceutical composition of claim 32, comprising: 1) Compound 1 at an amount of about 0.5 % w/w; 2) partially pregelatinized starch at an amount of about 19.5 % w/w and anhydrous lactose at an amount of about 61 % w/w; 3) colloidal silicon dioxide at an amount of about 1 % w/w; 4) fumaric acid at an amount of about 4 % w/w; 5) stearic acid at an amount of about 4 % w/w; and 6) sodium starch glycolate at an amount of about 10 % w/w.

63. The pharmaceutical composition of claim 62, having a total weight of about 100 mg.

64. The pharmaceutical composition of claim 63, which is contained in a size 3 capsule.

65. The pharmaceutical composition of claim 32, comprising: 1) Compound 1 at an amount of about 1 % w/w; 2) partially pregelatinized starch at an amount of about 19 % w/w and anhydrous lactose at an amount of about 61 % w/w; 3) colloidal silicon dioxide at an amount of about 1 % w/w; 4) fumaric acid at an amount of about 4 % w/w; 5) stearic acid at an amount of about 4 % w/w; and 6) sodium starch glycolate at an amount of about 10 % w/w.

66. The pharmaceutical composition of claim 65, having a total weight of about 200 mg.

67. The pharmaceutical composition of claim 66, which is contained in a size 2 capsule.

68. Use of a pharmaceutical composition of any one of claims 1-67 in the manufacture of a medicament for a method of treating multiple myeloma in a patient.

69. A process for preparing a pharmaceutical composition of any one of claims 1 to 67, comprising coating Compound 1, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, with a hydrophobic silica.

70. The process of claim 69, wherein the coating is conducted by blending Compound 1, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, and the hydrophobic silica to form a binary blend, before blending with additional excipients.

71. The process of claim 69 or 70, wherein the hydrophobic silica is silica dimethyl silylate.